GABA(B) receptor modulators potentiate baclofen-induced depression of dopamine neuron activity in the rat ventral tegmental area.

Ying Chen,keith g phillips,Gareth Minton,Emanuele Sher

DOI: https://doi.org/10.1038/sj.bjp.0706100

IF: 7.3

2005-01-01

British Journal of Pharmacology

Abstract:1 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) is a recently reported positive allosteric modulator of gamma-aminobutyric acid (GABA)(B) receptors. In this study, we assessed the ability of CGP7930 to modulate the baclofen-induced depression of dopamine (DA) neuron activity via the activation of GABA(B) receptors in the ventral tegmental area in rat midbrain slices. 2 The selective GABA(B) receptor agonist, baclofen, depressed the spontaneous firing rate of DA neurons in a concentration-dependent manner (EC50 = 0.27 mu M, n = 11). CGP7930 (30 mu M) significantly (P<0.05) shifted the baclofen concentration - response curve to the left (EC50 = 0.15 mu M, n = 5). The effects of baclofen alone or baclofen coapplied with CGP7930 were fully blocked by 1 mu M (2S)-3-[[(1S)-1-(3,4-dichloropheny) ethyl] amino-2-hydroxypropyl] ( phenylmethyl) phosphinic acid (CGP55845), a potent and selective GABA(B) receptor antagonist. 3 In similar experiments, N-[3,3-diphenylpropyl]-alpha-methylbenzylamine (fendiline) ( 30 or 50 mu M), a compound shown to potentiate GABA(B) receptor-mediated cortical hyperpolarisation, also significantly enhanced the inhibitory effect of baclofen. 4 It is therefore concluded that the recently reported GABA(B) receptor modulators, CGP7930 and fendiline, can enhance GABA(B) receptor-mediated depression of DA neuronal activity. This finding suggests a therapeutic potential for GABA(B) potentiators for the treatment of diseases associated with a hyperfunctional mesocorticolimbic system.